Vigilant Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Vigilant Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-83	Closed	-$6K	–	365
2020 Q2	$6K	Hold	83	–	–	﹤0.01%	294
2020 Q1	$4K	Hold	83	–	–	﹤0.01%	311
2019 Q4	$5K	Hold	83	–	–	﹤0.01%	447
2019 Q3	$5K	Hold	83	–	–	﹤0.01%	361
2019 Q2	$6K	Hold	83	–	–	﹤0.01%	357
2019 Q1	$7K	Hold	83	–	–	﹤0.01%	366
2018 Q4	$7K	Hold	83	–	–	﹤0.01%	388
2018 Q3	$14K	Hold	83	–	–	﹤0.01%	383
2018 Q2	$11K	Hold	83	–	–	﹤0.01%	410
2018 Q1	$9K	Buy	+83	New	+$8.21K	﹤0.01%	376

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Vigilant Capital Management's LGND Position: Q3 2020 in Review

Vigilant Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2020, closing a stake of 83 shares — an estimated $6K sold.

Vigilant Capital Management first reported a position in LGND in Q1 2018 and held it in 10 quarters. The position peaked at $14K in Q3 2018. 252 funds tracked by Wall St. Rank hold LGND as of Q3 2020.

Vigilant Capital Management reported no remaining Ligand Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Vigilant Capital Management sold 83 Ligand Pharmaceuticals shares in Q3 2020, an estimated $6K.
Vigilant Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2018 and held it in 10 quarters.
Vigilant Capital Management's Ligand Pharmaceuticals position peaked at $14K in Q3 2018.
252 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2020.

Based on Vigilant Capital Management's 13F filing for Q3 2020, filed 15 Oct 2020.